Featuring perspectives from Prof Susana Banerjee, including the following topics:
- Overview of the biology and treatment of low-grade serous ovarian cancer (0:00)
- Mechanism of action of avutometinib/defactinib (10:16)
- RAMP 201 Trial: Avutometinib/defactinib in recurrent low-grade serous ovarian cancer (14:32)
- Ongoing clinical trials in low-grade serous ovarian cancer (27:57)